Evidence map›Paper›PMID 36080490›Full record

ArticleMolecules (Basel, Switzerland)2022

Evolution of Interferon-Gamma Aptamer with Good Affinity and Analytical Utility by a Rational In Silico Base Mutagenesis Post-SELEX Strategy.

Lianhui Zhao, Qionglin Wang, Yingai Yin, Yan Yang, Huifang Cui, Yiyang Dong

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lianhui ZhaoCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Qionglin WangHenan Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou 450018, China.
Yingai YinCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Yan YangCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.
Huifang CuiCollege of Life Sciences, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0002-7270-4491
Yiyang DongCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China.

Funding

Beijing University of Chemical Technology-China-Japan Friendship Hospital Biomedical Trans-formation Engineering Research Center Joint Project RZ2020-02National Key Research and Development Program of China 2016YFF0203703
6 · The paper itself

Abstract

The Systematic Evolution of Ligands by EXponential enrichment (SELEX) is conventionally an effective method to identify aptamers, which are oligonucleotide sequences with desired properties to recognize targets specifically and sensitively. However, there are some inherent limitations, e.g., the loss of potential high-affinity sequences during biased iterative PCR enrichment processes and the limited structural diversity of the initial library, which seriously restrict their real-world applications. To overcome these limitations, the in silico base mutagenesis post-SELEX strategy based on the low Gibbs free energy (ΔG) and genetic algorithm was developed for the optimization of the interferon-gamma aptamer (B1-4). In the process of evolution, new sequences were created and the aptamer candidates with low ΔG values and advanced structures were produced. After five rounds of selection, systematic studies revealed that the affinity of the newly developed evolutionary aptamer (M5-5) was roughly 10-fold higher than that of the parent aptamer (B1-4), and an aptasensor detection system with a limit-of-detection (LOD) value of 3.17 nM was established based on the evolutionary aptamer. The proposed approach provided an efficient strategy to improve the aptamer with low energy and a high binding ability, and the good analytical utility thereof.

Indexed as

Aptamers, NucleotideSELEX Aptamer TechniqueInterferon-gammaLigandsMutagenesisAptamers, NucleotideInterferon-gammaLigandsaptamerbase mutagenesisin silicointerferon-gammapost-SELEX

Identifiers

PMID36080490
PMCPMC9457990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.